Top

BMC Geriatrics

Published in:

Open Access 01-12-2021 | Sarcopenia | Research

The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan

Authors: Yao Ma, Min He, Li-Sha Hou, Shen Xu, Zhi-Xin Huang, Na Zhao, Yan Kang, Ji-Rong Yue, Chenkai Wu

Published in: BMC Geriatrics | Issue 1/2021

Abstract

Background

Since the outbreak of COVID-19, it has been documented that old age and underlying illnesses are associated with poor prognosis among COVID-19 patients. However, it is unknown whether sarcopenia, a common geriatric syndrome, is associated with poor prognosis among older COVID-19 patients. The aim of our prospective cohort study is to investigate the association between sarcopenia risk and severe disease among COVID-19 patients aged ≥60 years.

Method

A prospective cohort study of 114 hospitalized older patients (≥60 years) with confirmed COVID-19 pneumonia between 7 February, 2020 and 6 April, 2020. Epidemiological, socio-demographic, clinical and laboratory data on admission and outcome data were extracted from electronic medical records. All patients were assessed for sarcopenia on admission using the SARC-F scale and the outcome was the development of the severe disease within 60 days. We used the Cox proportional hazards model to identify the association between sarcopenia and progression of disease defined as severe cases in a total of 2908 person-days.

Result

Of 114 patients (mean age 69.52 ± 7.25 years, 50% woman), 38 (33%) had a high risk of sarcopenia while 76 (67%) did not. We found that 43 (38%) patients progressed to severe cases. COVID-19 patients with higher risk sarcopenia were more likely to develop severe disease than those without (68% versus 22%, p < 0.001). After adjustment for demographic and clinical factors, higher risk sarcopenia was associated with a higher hazard of severe condition [hazard ratio = 2.87 (95% CI, 1.33–6.16)].

Conclusion

We found that COVID-19 patients with higher sarcopenia risk were more likely to develop severe condition. A clinician-friendly assessment of sarcopenia could help in early warning of older patients at high-risk with severe COVID-19 pneumonia.

Wu ZM, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. Jama. 2020;323(13):1239–42. https://doi.org/10.1001/jama.2020.2648.CrossRefPubMed

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032.CrossRefPubMed

WHO Coronavirus (COVID-19) Dashboard. [https://covid19.who.int/].

Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441–7. https://doi.org/10.1002/jmv.25689.CrossRefPubMedPubMedCentral

Wu P, Hao X, Lau EHY, Wong JY, Leung KSM, Wu JT, et al. Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020. Euro Surveill. 2020;25(3):2000044.

Wilson NKA, Barnard LT, Baker M. Estimating the Case Fatality Risk of COVID-19 using Cases from Outside China. medRxiv preprint. https://doi.org/10.1101/2020.02.15.20023499.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8. https://doi.org/10.1016/j.jaci.2020.04.006.CrossRefPubMedPubMedCentral

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. Bmj. 2020;368:m1198.CrossRefPubMed

10.

Epidemiology Working Group for NCIP Epidemic Response CCfDCaP. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China (in chinese). Chin J Epidemiol. 2020;41(2):145–51.

11.

Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19)—United States, February 12–March 16, 2020. [https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w].

12.

World Health Organization, Europe (April 2, 2020).Statement – Older people are at highest risk from COVID-19, but all must act to prevent community spread. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19/statements/statement-older-people-are-at-highest-risk-fromcovid-19,-but-all-mustact-to-prevent-community-spread.

13.

Epidemiologic and methodologic problems in determining nutritional status of older persons. Proceedings of a conference. Albuquerque, New Mexico, October 19-21, 1988, Am. J Clin Nutr. 1989;50(5 Suppl):1121–235.

14.

Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56(3):M146–56. https://doi.org/10.1093/gerona/56.3.M146.CrossRefPubMed

15.

Castillo EM, Goodman-Gruen D, Kritz-Silverstein D, Morton DJ, Wingard DL, Barrett-Connor E. Sarcopenia in elderly men and women: the rancho Bernardo study. Am J Prev Med. 2003;25(3):226–31. https://doi.org/10.1016/S0749-3797(03)00197-1.CrossRefPubMed

16.

Janssen I. Influence of sarcopenia on the development of physical disability: the cardiovascular health study. J Am Geriatr Soc. 2006;54(1):56–62. https://doi.org/10.1111/j.1532-5415.2005.00540.x.CrossRefPubMed

17.

Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di Iorio A, et al. Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985). 2003;95(5):1851–60.CrossRef

18.

Zeng Y, Hu X, Xie L, Han Z, Zuo Y, Yang M. The prevalence of sarcopenia in Chinese elderly nursing home residents: a comparison of 4 diagnostic criteria. J Am Med Dir Assoc. 2018;19(8):690–5. https://doi.org/10.1016/j.jamda.2018.04.015.CrossRefPubMed

19.

Hsu CS, Kao JH. Sarcopenia and chronic liver diseases. Expert Rev Gastroenterol Hepatol. 2018;12(12):1229–44. https://doi.org/10.1080/17474124.2018.1534586.CrossRefPubMed

20.

Ma Y, Hou L, Yang X, Huang Z, Yang X, Zhao N, et al. The association between frailty and severe disease among COVID-19 patients aged over 60 years in China: a prospective cohort study. BMC Med. 2020;18(1):274. https://doi.org/10.1186/s12916-020-01761-0.CrossRefPubMedPubMedCentral

21.

Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health. 2020;5(8):e444–51. https://doi.org/10.1016/S2468-2667(20)30146-8.CrossRefPubMedPubMedCentral

22.

Bollheimer LC, Buettner R, Pongratz G, Brunner-Ploss R, Hechtl C, Banas M, et al. Sarcopenia in the aging high-fat fed rat: a pilot study for modeling sarcopenic obesity in rodents. Biogerontology. 2012;13(6):609–20. https://doi.org/10.1007/s10522-012-9405-4.CrossRefPubMed

23.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23. https://doi.org/10.1093/ageing/afq034.CrossRefPubMedPubMedCentral

24.

Malmstrom TK, Miller DK, Simonsick EM, Ferrucci L, Morley JE. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016;7(1):28–36. https://doi.org/10.1002/jcsm.12048.CrossRefPubMed

25.

Organization WH: Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance. 2020.

26.

China NHCotPsRo: Diagnosis and treatment protocol for novel coronavirus infection-induced pneumonia version 7 (trial). 2020.

27.

Organization WH. WHO Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected; 2019. p. 12.

28.

ARDS Definition Task Force R, V. M, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, et al. Acute respiratory distress syndrome: the Berlin Definition. Jama. 2012;307(23):2526–33.

29.

Sheean PM, Peterson SJ, Gomez Perez S, Troy KL, Patel A, Sclamberg JS, et al. The prevalence of sarcopenia in patients with respiratory failure classified as normally nourished using computed tomography and subjective global assessment. JPEN J Parenter Enteral Nutr. 2014;38(7):873–9. https://doi.org/10.1177/0148607113500308.CrossRefPubMed

30.

Yardimci B, Aksoy SM, Ozkaya I, Demir T, Tezcan G, Kaptanoglu AY. Anthropometric measurements may be informative for nursing home-acquired pneumonia. Pak J Med Sci. 2016;32(3):694–9. https://doi.org/10.12669/pjms.323.9635.CrossRefPubMedPubMedCentral

31.

Altuna-Venegas S, Aliaga-Vega R, Maguiña JL, Parodi JF, Runzer-Colmenares FM. Risk of community-acquired pneumonia in older adults with sarcopenia of a hospital from Callao, Peru 2010-2015. Arch Gerontol Geriatr. 2019;82:100–5. https://doi.org/10.1016/j.archger.2019.01.008.CrossRefPubMedPubMedCentral

32.

Maeda K, Akagi J. Muscle mass loss is a potential predictor of 90-day mortality in older adults with aspiration pneumonia. J Am Geriatr Soc. 2017;65(1):e18–22. https://doi.org/10.1111/jgs.14543.CrossRefPubMed

33.

Wakabayashi H, Sakuma K. Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management. J Cachexia Sarcopenia Muscle. 2014;5(4):269–77. https://doi.org/10.1007/s13539-014-0162-x.CrossRefPubMedPubMedCentral

34.

Maeda K, Akagi J. Sarcopenia is an independent risk factor of dysphagia in hospitalized older people. Geriatr Gerontol Int. 2016;16(4):515–21. https://doi.org/10.1111/ggi.12486.CrossRefPubMed

35.

Wakabayashi H. Presbyphagia and Sarcopenic dysphagia: association between aging, sarcopenia, and deglutition disorders. J Frailty Aging. 2014;3(2):97–103. https://doi.org/10.14283/jfa.2014.8.CrossRefPubMed

36.

Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis. J Inf Secur. 2020;81(2):e16–25.

37.

Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Inf Secur. 2020;80(6):e14–8.

38.

Can B, Kara O, Kizilarslanoglu MC, Arik G, Aycicek GS, Sumer F, et al. Serum markers of inflammation and oxidative stress in sarcopenia. Aging Clin Exp Res. 2017;29(4):745–52. https://doi.org/10.1007/s40520-016-0626-2.CrossRefPubMed

39.

Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev. 2019;56:100980. https://doi.org/10.1016/j.arr.2019.100980.CrossRefPubMed

40.

Bano G, Trevisan C, Carraro S, Solmi M, Luchini C, Stubbs B, et al. Inflammation and sarcopenia: a systematic review and meta-analysis. Maturitas. 2017;96:10–5. https://doi.org/10.1016/j.maturitas.2016.11.006.CrossRefPubMed

41.

Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020;42(2):505–14. https://doi.org/10.1007/s11357-020-00186-0.CrossRefPubMedPubMedCentral

42.

Kadkhoda K. COVID-19: an Immunopathological View. mSphere. 2020;5(2):e00344–20.

43.

Constantin D, Menon MK, Houchen-Wolloff L, Morgan MD, Singh SJ, Greenhaff P, et al. Skeletal muscle molecular responses to resistance training and dietary supplementation in COPD. Thorax. 2013;68(7):625–33. https://doi.org/10.1136/thoraxjnl-2012-202764.CrossRefPubMed

44.

Nelke C, Dziewas R, Minnerup J, Meuth SG, Ruck T. Skeletal muscle as potential central link between sarcopenia and immune senescence. EBioMedicine. 2019;49:381–8. https://doi.org/10.1016/j.ebiom.2019.10.034.CrossRefPubMedPubMedCentral

45.

McGonagle D, Sharif K, O'Regan A, Bridgewood C. The role of cytokines including Interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537. https://doi.org/10.1016/j.autrev.2020.102537.CrossRefPubMedPubMedCentral

46.

Liu B, Li M, Zhou Z, Guan X, Xiang Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? J Autoimmun. 2020;111:102452. https://doi.org/10.1016/j.jaut.2020.102452.CrossRefPubMedPubMedCentral

47.

Dalle S, Rossmeislova L, Koppo K. The role of inflammation in age-related sarcopenia. Front Physiol. 2017;8:1045. https://doi.org/10.3389/fphys.2017.01045.CrossRefPubMedPubMedCentral

48.

Alemán H, Esparza J, Ramirez FA, Astiazaran H, Payette H. Longitudinal evidence on the association between interleukin-6 and C-reactive protein with the loss of total appendicular skeletal muscle in free-living older men and women. Age Ageing. 2011;40(4):469–75. https://doi.org/10.1093/ageing/afr040.CrossRefPubMed

49.

Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. https://doi.org/10.1016/j.ijantimicag.2020.105954.CrossRefPubMedPubMedCentral

50.

Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–5. https://doi.org/10.1172/JCI137647.CrossRefPubMedPubMedCentral

51.

Ida S, Nakai M, Ito S, Ishihara Y, Imataka K, Uchida A, et al. Association Between Sarcopenia and Mild Cognitive Impairment Using the Japanese Version of the SARC-F in Elderly Patients With Diabetes. J Am Med Dir Assoc. 2017;18(9):809.e809–13.CrossRef

52.

Ida S, Murata K, Nakadachi D, Ishihara Y, Imataka K, Uchida A, et al. Development of a Japanese version of the SARC-F for diabetic patients: an examination of reliability and validity. Aging Clin Exp Res. 2017;29(5):935–42. https://doi.org/10.1007/s40520-016-0668-5.CrossRefPubMed

53.

Parra-Rodríguez L, Szlejf C, García-González AI, Malmstrom TK, Cruz-Arenas E, Rosas-Carrasco O. Cross-cultural adaptation and validation of the Spanish-language version of the SARC-F to assess sarcopenia in Mexican community-dwelling older adults. J Am Med Dir Assoc. 2016;17(12):1142–6. https://doi.org/10.1016/j.jamda.2016.09.008.CrossRefPubMed

Title: The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan
Authors: Yao Ma
Min He
Li-Sha Hou
Shen Xu
Zhi-Xin Huang
Na Zhao
Yan Kang
Ji-Rong Yue
Chenkai Wu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Sarcopenia
COVID-19
Published in: BMC Geriatrics / Issue 1/2021
Electronic ISSN: 1471-2318
DOI: https://doi.org/10.1186/s12877-021-02310-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The role of SARC-F scale in predicting progression risk of COVID-19 in elderly patients: a prospective cohort study in Wuhan

Abstract

Background

Method

Result

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Method

Result

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Association of life course socioeconomic status and adult height with cognitive functioning of older adults in India and China

Implementation of an integrative movement program for residents with dementia in a VA nursing home

Facilitators and barriers to implement nurse-led interventions in long-term dementia care: a qualitative interview study with Swiss nursing experts and managers

The performance of the Dutch Safety Management System frailty tool to predict the risk of readmission or mortality in older hospitalised cardiac patients

Contribution of IQ in young adulthood to the associations of education and occupation with cognitive ability in older age

Patient factors associated with new prescribing of potentially inappropriate medications in multimorbid US older adults using multiple medications

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page